TVTX - Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
- Shares of Travere Therapeutics remain well below this year's highs despite PROTECT study success.
- The regulatory update on the FSGS indication of sparsentan has weighed on the share price along with the poor biotech sentiment.
- While there is uncertainty for the FSGS indication, the larger IgAN indication looks in much better position with regulatory given the eGFR language in the press release.
- Pegtibatinase phase 1/2 trial results represent another catalyst for the stock this year.
For further details see:
Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success